Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX:PBT) covers the month of November 2018, with the report dated November 16, 2018. The registrant is a foreign private issuer based in Australia. The filing primarily discloses a Change of Director's Interest Notice pursuant to ASX Listing Rule 3.19A.2 and Section 205G of the Corporations Act.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director holdings and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed is an increase in the securities held by Director Dr. Ira Shoulson:
- Director: Dr. Ira Shoulson
- Date of Change: November 16, 2018
- Security Class: Unlisted Options (PBTAAA)
- Change Type: Acquisition of 1,250,000 options via direct interest.
- Consideration: Nil consideration.
- Holdings After Change: 1,250,000 options (Direct); 0 shares.
- Reason: Issue of unlisted options to the director as approved by shareholders on November 17, 2017.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notice of a change in director interest and confirms that the transaction did not occur during a closed period requiring prior written clearance.
Investor Verification Checklist
- Verify the terms and vesting schedule of the 1,250,000 unlisted options (PBTAAA) granted to Dr. Ira Shoulson.
- Confirm the shareholder approval details from November 17, 2017, regarding the option grant.
- Check for any subsequent filings regarding the exercise or expiration of these options.
- Review the company's latest Form 20-F for comprehensive financial data, as this 6-K contains no financial metrics.